Mizuho Securities analyst Salim Syed maintained a Buy rating on Coherus Biosciences (NASDAQ:CHRS) on Monday, setting a price target of $30, which is approximately 59.57% above the present share price of $18.8.
Syed expects Coherus Biosciences to post earnings per share (EPS) of $0.39 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Coherus Biosciences, with an average price target of $30.
The analysts price targets range from a high of $32 to a low of $27.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $113.55 million and a net profit of $33.72 million. The company's market cap is $1.35 billion.
According to TipRanks.com, Mizuho Securities analyst Salim Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.8% and a 48.33% success rate.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood (NYSE:RWT) City, CA.